Sanofi halts MOBILIZE phase 3 study for riliprubart

Sanofi today announced the discontinuation of the MOBILIZE phase 3 study evaluating riliprubart in patients with chronic inflammatory demyelinating polyneuropathy (CIDP) refractory to standard-of-care treatment. The decision follows an interim analysis by an independent data monitoring committee, which concluded that the study is unlikely to provide sufficient efficacy. Despite the termination, the analysis identified no safety signals related to riliprubart.

The company stated that the termination of the MOBILIZE study will not incur any significant financial cost. Consequently, there is no change to the financial guidance for 2026. Sanofi will work with investigators and site teams to ensure a wind-down of the study, including the appropriate transition of care for all enrolled patients. A thorough analysis of the data will be conducted to inform future research directions.

Study Details and Future Evaluation

The MOBILIZE study (clinical study identifier: NCT06290128) focused on patients who did not respond to standard-of-care treatments. While this specific trial is stopping, Sanofi noted that the continuation of other ongoing studies with riliprubart will be evaluated accordingly. This includes the VITALIZE phase 3 study (clinical study identifier: NCT06290141) in IVIg-treated patients with CIDP.

Study Name	Identifier	Patient Population	Status
MOBILIZE	NCT06290128	Refractory to standard-of-care	Stopped
VITALIZE	NCT06290141	IVIg-treated	Ongoing

About Riliprubart

Riliprubart (SAR445088, BIVV020) is an IgG4 humanized monoclonal antibody designed to selectively inhibit activated C1s in the classical complement pathway. By blocking C1s, the drug aims to inhibit key inflammatory mechanisms that drive demyelination and axonal damage in CIDP. The safety and efficacy of riliprubart have not yet been evaluated by any regulatory authority.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-0.78%	-1.84%	-4.47%	-26.44%	-49.37%	-59.55%

Sanofi India Limited has appointed Mr. Debajit Roy as the Sales & Customer Engagement Head – Diabetes, designating him as Senior Management Personnel effective from June 8, 2026. The decision aims to strengthen the company's leadership in the Diabetes segment as it continues to drive growth across key therapy areas.

The appointment was approved by the Board of Directors via a circular resolution passed on June 3, 2026. This decision was based on the recommendation of the Nomination and Remuneration Committee, which passed its resolution by circulation on June 2, 2026. The approval from the majority of the Board was received at 11:40 a.m.

Profile of the Appointee

Mr. Roy brings over 20 years of experience driving growth, transformation, and performance across Dermatology, Specialty Care, Diabetes, and Cardiovascular therapies. Prior to this role, he served as Vice President at Gracewell Specialty and Gracemax, part of Glenmark Pharmaceuticals.

He holds an MBA in Marketing and Human Resources from the Institute of Information and Management Science in Bhubaneshwar and a Bachelor of Science from the University of Calcutta.

Appointment Details

The following table outlines the key details of the appointment:

Sr. No.	Particulars	Description
1.	Reason for change	Appointment of Mr. Debajit Roy as Sales & Customer Engagement Head – Diabetes and designated as Senior Management Personnel of the Company
2.	Date of appointment & term	Date of Appointment – With effect from June 8, 2026 Term of Appointment – Whole-time Employment
3.	Brief profile	A Business leader with over 20 years of experience driving growth, transformation, and performance across Dermatology, Specialty Care, Diabetes, and Cardiovascular therapies. In his most recent stint, he has been as Vice President -in Gracewell Specialty and Gracemax, Glenmark Pharmaceuticals. He holds degree of MBA in Marketing and Human Resources from Institute of Information and Management Science - Bhubaneshwar and Bachelor of Science from University of Calcutta.
4.	Disclosure of relationships	Not Applicable

The disclosure was made in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and read with Schedule III of the Listing Regulations and SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026.